Chicago, IL (August 28, 1998) --The volatile week has drawn to a close, and we're hardly the worse for it. Though our stocks didn't rise, they continue to represent market-leading companies, and their value is backed by rising assets and growing businesses -- by new drugs from Johnson & Johnson, new chips from Intel, and new acquisitions at Campbell Soup.
A stock price is never just a number, devoid of a "soul" -- for lack of a better description. Every ticker symbol represents a company that, in the case with our three investments, employs tens of thousands of people, all of them working to make a living and to help their company grow.
The past week we addressed a myriad of topics for the Drip Port. On Monday, we announced that we're sending $200 to buy more Campbell Soup (NYSE: CPB) and we explained why. We also discussed possible actions to take with our future dividend payments from Campbell, if we choose not to reinvest them due to fees. On Tuesday, we talked about the importance of dividends and how, decades from now, a company that grows its dividend could be paying you, for example, a 48% annual yield on your initial investment in dividends alone. Math can go a long way in explaining why stocks beat other investment options over the long term. The column was called "Livin' on Dividends."
On Wednesday, we returned to our banking decision, reviewing U.S. Bancorp's (NYSE: USB) biz and our past columns on the company. USB is a strong finalist, alongside Mellon Bank (NYSE: MEL) and Norwest. We'll review Norwest (NYSE: NOB) next week. It's our last finalist to review.
On Thursday, we took a detour and discussed the sharply declining stock market. The column was titled "Time to Surrender."
If you have questions or comments on the week, or comments for next week (or on anything), please visit the Drip message boards linked in the top right of this page.
Until Monday, have a Foolish weekend!